WO2009081587A1 - 皮膚外用剤 - Google Patents
皮膚外用剤 Download PDFInfo
- Publication number
- WO2009081587A1 WO2009081587A1 PCT/JP2008/003954 JP2008003954W WO2009081587A1 WO 2009081587 A1 WO2009081587 A1 WO 2009081587A1 JP 2008003954 W JP2008003954 W JP 2008003954W WO 2009081587 A1 WO2009081587 A1 WO 2009081587A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- external preparation
- fatty acid
- extract
- rhododendrol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Definitions
- the present invention relates to a skin beautifying agent having little skin irritation and excellent long-term storage stability and a skin whitening agent having a high whitening effect.
- preservatives such as paraoxybenzoic acids and phenoxyethanol are commonly used for topical skin preparations that are usually prescribed as cosmetics in order to prevent spoilage and alteration by microorganisms. Has been.
- Rhododendrol and its derivatives are already known as ingredients for preventing and improving skin pigmentation such as stains and freckles (see Patent Documents 1 to 3). It is not known to be used for the purpose.
- rhododendrol and its derivatives have low solubility in water, and polyoxyethylene used as a solubilizer to improve the stability of the formulation in formulations containing these, especially lotions having little viscosity. It is necessary to devise a method of using an additional nonionic surfactant more than usual and further combining with a lower alcohol, which contributes to enhancing skin irritation.
- the present invention includes (a) one or more selected from rhododendrol represented by the following general formula (1) and derivatives thereof, and (b) one selected from sucrose fatty acid esters and polyglycerol fatty acid esters.
- the present invention provides a skin external preparation characterized by containing two or more kinds and (c) a polyhydric alcohol.
- R is a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or disaccharide.
- the present invention provides a skin external preparation with less irritation by stably adding rhododendrol and its derivatives to a skin external preparation, and at the same time reducing the amount of surfactants and preservatives that are considered to cause skin irritation. To do.
- the present inventors have used rhododendrol and / or a derivative thereof in combination with a sucrose fatty acid ester and / or polyglycerin fatty acid ester and a polyhydric alcohol. It was found that an external preparation for skin having excellent formulation stability, low skin irritation and excellent antiseptic and antifungal effects can be obtained.
- an external preparation for skin capable of stably blending rhododendrol and its derivatives.
- a polyoxyethylene addition type nonionic surfactant having a problem of skin irritation can be suppressed, the skin irritation can be reduced.
- rhododendrol and its derivatives themselves are excellent in antiseptic and antifungal effects, it is possible to suppress the use of conventional preservatives such as paraoxybenzoic acid esters and phenoxyethanol, so that the skin irritation caused by these preservatives can also be reduced. Therefore, it is possible to provide an external preparation for skin that is superior in terms of safety.
- rhododendrol represented by the following general formula (1) or a derivative thereof is blended as the component (a).
- R is a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or disaccharide.
- Rhododendrol [4- (p-hydroxyphenyl) -2-butanol] in which R is a hydrogen atom in the above general formula (1) is a known compound, and is also included in Meglinoki (Acer nikoence Maxim.) And the like. It is known.
- the rhododendrol may be synthesized by a conventionally known method or a commercially available product may be used. Moreover, you may use what was refine
- the rhododendrol and rhododendrol derivatives used in the present invention have optical isomers, but the (+) isomer, the ( ⁇ ) isomer alone, or a mixture thereof (denoted as ( ⁇ )), -251548) can also be used.
- acylated rhododendrol in which R is an acyl group having 2 to 20 carbon atoms is particularly limited as long as it is generally used. Is not to be done.
- the acylated rhododendrol can be easily obtained by acylating the rhododendrol by a conventionally known method.
- examples of the acyl group include an acetyl group, a propionyl group, a butyryl group, a pentanoyl group, a hexanoyl group, a decanoyl group, and the like.
- acylated rhododendrol used in the present invention include (+) isomer, ( ⁇ ) isomer, and ( ⁇ ) such as hexanoyl rhododendrol and acetyl rhododendrol.
- the sugar residue in the rhododendrol glycoside where R is a sugar residue is a reducing monosaccharide or disaccharide.
- Specific examples include monosaccharides such as glucose, galactose, xylose, mannose and N-acetylglucosamine, and disaccharides such as maltose, cellobiose and gentibiose.
- isomers having an ⁇ bond and a ⁇ bond there are isomers having an ⁇ bond and a ⁇ bond, and these can be used alone or a mixture thereof.
- the rhododendrol glycoside of the present invention can be obtained using a method already known as a method for synthesizing arbutin (USP No. 3121385).
- a method for synthesizing arbutin USP No. 3121385.
- Rhododendrol glycoside can be easily obtained as white powder crystals. It can also be obtained by reducing raspberry ketone glycosides. It is also possible to isolate from natural products.
- the glycosides of the present invention have optical isomers, but (+) isomer, ( ⁇ ) isomer alone or a mixture ( ⁇ ) thereof can also be used.
- glycosides used in the present invention include rhododendrol-D-glucoside ( ⁇ and ⁇ forms), rhododendrol-D-galactoside ( ⁇ and ⁇ forms), rhododendrol-D-xyloside ( (+) isomer, ( ⁇ ) isomer, ( ⁇ ) isomer, etc., such as ⁇ and ⁇ isomers) and rhododendrol-D-maltoside ( ⁇ and ⁇ isomers).
- rhododendrol is particularly preferred from the standpoint of antiseptic / antifungal effects, skin irritation and the like.
- the content of the component (a) used in the present invention in the case of rhododendrol in which R is a hydrogen atom in the general formula (1), 0.1 to 3% by mass based on the total amount of the external preparation for skin, 0.2 to 3% by mass, particularly 0.5 to 3% by mass is preferable. Further, in the case of acylated rhododendrol in which R is an acyl group having 2 to 20 carbon atoms, 0.1 to 5% by mass, further 0.5 to 5% by mass, particularly 1 to 5% by mass based on the total amount of the external preparation for skin. 5 mass% is preferable.
- rhododendrol glycoside in which R is a sugar residue, 0.1 to 5% by mass, further 0.5 to 5% by mass, especially 1 to 5% by mass, based on the total amount of the external preparation for skin. preferable.
- the content is within these ranges, the antiseptic / antifungal effect can be exhibited effectively, and a wide degree of freedom in the formulation of the external preparation for skin can be obtained.
- a nonionic surfactant selected from sucrose fatty acid ester and polyglycerin fatty acid ester as component (b) and a polyhydric alcohol as component (c) are combined. To do.
- sucrose fatty acid ester examples include sucrose mono-fatty acid ester, sucrose di-fatty acid ester, sucrose tri-fatty acid ester, etc.
- the ester distribution is based on the total amount of sucrose fatty acid ester. It is preferable to use a mixed sucrose fatty acid ester having a distribution of 60 to 90% by mass of mono fatty acid ester and 5 to 40% by mass of sucrose difatty acid ester.
- the fatty acid in the sucrose fatty acid ester is a saturated or unsaturated fatty acid having 12 to 18 carbon atoms, and lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid and the like can be preferably exemplified.
- sucrose monofatty acid ester having a high blending ratio examples include sucrose monolaurate and sucrose monostearate.
- the average degree of polymerization of glycerol in the polyglycerol fatty acid ester used in the present invention is preferably 2 to 16.
- Examples of the degree of esterification include monoesters, diesters, and triesters.
- monoesters having an average degree of polymerization of glycerol of 2 to 10 are preferably used.
- the fatty acid in the polyglycerol fatty acid ester used in the present invention is preferably a fatty acid having 10 to 18 carbon atoms.
- Particularly preferred examples include lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, and behenic acid.
- polyglycerol fatty acid esters used in the present invention are commercially available, and particularly preferable examples include decaglycerol monolaurate, decaglycerol monooleate, and decaglycerol monostearate.
- the specific nonionic surfactant (b) used in the present invention preferably has an HLB value of 10 or more, particularly 11 to 18. If it is this range, the mixing
- the mixed HLB value should just be in the said range, and the HLB value of some nonionic surfactants may be 10 or less.
- the mixed HLB value is calculated by summing the HLB values of the individual nonionic surfactants multiplied by the respective proportions.
- the HLB values for individual nonionic surfactants are T.A. Davis and B.B. K. Rideal, Interfacial Phenomea, Academic Press, New York 1963, pp. It can be calculated according to 371-383.
- polyhydric alcohol (c) used in the present invention examples include glycerin, diglycerin, 1,3-butylene glycol, polyethylene glycol, dipropylene glycol, propylene glycol, hexylene glycol, isoprene glycol, erythritol, xylitol, maltitol. , Trehalose, sorbitol and the like.
- glycerin, 1,3-butylene glycol, and dipropylene glycol are particularly preferable.
- the component (b) plays the role of solubilizing the component (a) together with the component (c).
- the skin external preparation When the skin external preparation is made into an emulsion, it also serves as an emulsifier, and the stability of the preparation Involved in.
- the content of the specific nonionic surfactant that is component (b) of the present invention is preferably 0.01 to 5% by mass, more preferably 0.05 to 3%, based on the total amount of the external preparation for skin. % By mass. In the range of these contents, the solubilization, emulsification and dispersion actions, which are basic functions as a surfactant, are good, and at the same time, the usability of the external preparation for skin is excellent. In addition, the irritation caused by the surfactant is less likely to occur.
- the content of the polyhydric alcohol as component (c) is preferably 0.1 to 30% by mass, more preferably 1.0 to 20% by mass, based on the total amount of the external preparation for skin. In the range of these contents, the solubilization, emulsification and dispersion actions, which are basic functions as a surfactant, are good, and at the same time, the usability of the external preparation for skin is also excellent.
- the rhododendrol or derivative thereof used in the present invention has an excellent antibacterial action by itself and contains paraoxybenzoic acid ester and / or phenoxyethanol, which is added for the purpose of preventing primary and secondary contamination of the preparation. Even if not, it is possible to prevent spoilage and alteration of the preparation by microorganisms. Therefore, it is preferable that the external preparation for skin of the present invention contains substantially no paraoxybenzoic acid ester and / or phenoxyethanol.
- the skin external preparation of the present invention may further contain the Chinese name “Fire Thorn”.
- “Fire Thorn” is a kind of Rosaceae Pyracantha, and its fruit is known as the Chinese name “Red Yoko”, which keeps the spleen healthy and has a known medicinal effect such as treatment of indigestion. Further, it has a tyrosinase activity inhibitory effect and a melanin production inhibitory effect, and a whitening cosmetic material containing this extract has been proposed (Japanese Patent Laid-Open No. 5-55870).
- fire spine extract The active ingredient of the Chinese name “Red Yoko”, which is the fruit of this “fire spine” (hereinafter abbreviated as “fire spine extract”), is extracted with water, lower alcohol such as methanol, ethanol or propanol or a mixture thereof.
- the extract can be directly blended into an external preparation for skin, but it is preferable to use it by pulverizing it by freeze drying or spray drying. It is also possible to add a liquid or powdered product by purifying the extract by means such as liquid-liquid distribution or adsorption chromatography.
- the fire thorn extract obtained in this way can be blended as a reducing agent that suppresses browning of the preparation due to high temperature and light.
- the content of the fire spine extract as component (d) is preferably 0.001 to 5% by mass in terms of solid matter of the extract, based on the total amount of external preparation for skin, More preferably, the content is 0.005 to 2% by mass. If it is these ranges, it is possible to suppress the browning of a formulation more effectively.
- component (b) when it contains a polyoxyethylene addition type nonionic surfactant, depending on its blending balance, the function of component (b) is hindered, and stable blending of rhododendrol or its derivatives Therefore, it is particularly preferable that the content of the component (b) is 50% by mass or less, preferably 20% by mass or less, and not substantially contained.
- any dosage form such as ointments, lotions, emulsions, creams, packs and the like can be used.
- the stability of the preparation was evaluated by turbidity, appearance evaluation of precipitation, discoloration evaluation under accelerated conditions, and discoloration evaluation under sun exposure.
- skin irritation was evaluated by skin irritation using a female panel, and antiseptic and antifungal properties were evaluated by using standard bacteria. Each specific test method is described below.
- Example 2 is an Example of the present application, but because the content ratio of the specific nonionic surfactant as the component (b) to the total nonionic surfactant is low, the stability of the preparation was slightly inferior. It has become.
- Example 15 is a case where no fire thorn extract is contained, but although it is excellent in formulation stability and antiseptic / antifungal properties with respect to turbidity / precipitation, it is inferior in discoloration stability under high temperature and exposure to sunlight. It can be seen that the thorn extract greatly contributes to the discoloration stability.
- Example 22 is excellent in formulation stability, since it contains a relatively large amount of nonionic surfactant, it may cause skin irritation in actual use.
- Example 24 is also excellent in the stability of the preparation, but contains a relatively large amount of polyhydric alcohol, so that there is a risk of stickiness in terms of feel in actual use.
- Table 4 shows the results of skin irritation evaluation for Examples 1, 12, 13, 14 and Comparative Example 4 described above.
- Examples 1, 12, and 13 of the present invention have almost no skin irritation and are excellent in safety, but when preservatives commonly used with rhododendrol are methyl paraoxybenzoate and phenoxyethanol, It can be seen that skin irritation occurs (Example 14).
- Comparative Example 4 is a case where an active agent of polyoxyethylene addition type, which is a nonionic surfactant that is usually used, is used in place of the specific nonionic surfactant of the present application. It turns out that it is inferior in terms of sex.
- the skin lotion shown in Table 5 and the emulsified composition shown in Table 6 were prepared by a conventional method and subjected to the above evaluation test. As a result, excellent results were obtained.
- a skin external preparation was prepared by a conventional method and subjected to the above various evaluation tests. As a result, it was confirmed that the preparation was excellent in stability and antiseptic / antifungal properties and was not irritating to the skin.
- Table 7 shows the composition of the fragrance used in the above application example.
- an external preparation for skin having a low skin irritation and excellent long-term storage stability and having a high skin whitening effect and a whitening effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
含有量がこれらの範囲であれば、防腐・防黴効果が有効に発揮できると共に、皮膚外用剤の処方における幅広い自由度を得ることが可能となる。
なお、非イオン界面活性剤を2種以上混合して使用する場合は、その混合HLB値が上記範囲にあればよく、一部の非イオン界面活性剤のHLB値は10以下であってもよい。ここで、混合HLB値は、個々の非イオン界面活性剤のHLB値にそれぞれの割合を乗じたものを合計することにより計算される。
個々の非イオン界面活性剤のHLB値は、J.T.Davies and B.K.Rideal,Interfacial Phenomea,Academic Press,New York 1963,pp.371-383に従って、算出することができる。
評価試料を、45℃で2ヶ月保存したものについて、その外観(濁り・沈殿の有無)を、以下の基準に従って、目視で評価した。
×:多量の沈殿又は濁りあり
△:沈殿又は濁りあり
○:わずかに沈殿又は濁りあり
◎:沈殿・濁りなし
評価試料を、60℃で1ヶ月間保存したものについて、その変色の程度を、以下の基準に従って、目視で比較し評価した。
×:強く変色
△:変色あり
○:わずかに変色
◎:変色なし
評価試料を、日光暴露下にて1週間保存したものについて、その変色の程度を、以下の基準に従って、目視で比較し評価した。
×:強く変色
△:変色あり
○:わずかに変色
◎:変色なし
敏感肌であると自認している女性パネル(20~50代)20名により評価した。女性パネルは、被験試料を朝晩2回、3日間連続で使用し、最終日に以下の基準に従って、皮膚刺激性に関する使用感を評価した。1回にひとつの評価試料を評価し、2日間の休止期間を設けた後、同様にして次の評価試料を評価した。
スコア3:刺激を感じる
スコア2:やや刺激を感じる
スコア1:ほとんど刺激を感じない
スコア0:まったく刺激を感じない
の4段階の基準にあわせて行った。結果を出現例数として、表4に示す。これより、本発明の皮膚外用剤は、刺激性の低さにおいても優れていることを確認した。
標準菌として指定された真菌[黴(Aspergillus niger ATCC 16404)、酵母(Candida albicans ATCC 10231)]及び細菌(Escherichia coli ATCC 8739)株を用い、黴の胞子若しくは48時間前培養した酵母を、評価試料1g当たり1×105colony forming unit(以下、cfu)になるように、又は24時間前培養した細菌を、評価試料1g当たり1×106cfuになるように接種し、室温下に放置した。接種後1~28日までの経日で評価試料中の生残微生物数を計測し、以下の基準に従って、3段階にて評価した。尚、黴、酵母、細菌それぞれについての評価のうちの一番低い評価を、防腐防黴性に関する総合評価とした。
表1~3に示す処方に従って、化粧水を常法にて調製し、上記の各種評価試験を行った。その結果も併せて示す。
原料成分 配合量
1,3-ブチレングルコール 2.0
ジプロピレングリコール 6.0
濃グリセリン 5.0
ロドデンドロール 1.5
グリチルリチン酸ジカリウム 0.2
ショ糖脂肪酸エステル(注4) 0.3
ヒアルロン酸ナトリウム 0.01
火棘抽出物 0.1
カンゾウフラボノイド(*1) 0.01
ラフィノース(*2) 0.05
ヒマラヤンラズベリー根エキス(*3) 0.05
セイヨウニワトコエキス(*4) 0.01
オウレンエキス(*5) 0.01
テンニンカエキス(*6) 0.01
精製水 残 量
*1;油溶性甘草エキスP-T(40)(丸善製薬社製)
*2;オリゴGGF(旭化成工業製)
*3;ヒマラヤンラズベリー抽出液BG80(丸善製薬社製)
*4;ニワトコ抽出液BG(丸善製薬社製)
*5;オウレン抽出液-J(丸善製薬社製)
*6;テンニンカ抽出液BG80(丸善製薬社製)
原料成分 配合量
エタノール 5.0
ロドデンドロール 2.0
ショ糖脂肪酸エステル(注1) 0.5
メチルフェニルポリシロキサン(*7) 1.0
メチルポリシロキサン(*8) 1.0
トリ2-エチルヘキサン酸グリセリル 1.0
パラメトキシケイ皮酸2-エチルヘキシル 0.1
ジプロピレングリコール 3.0
濃グリセリン 2.0
カルボキシビニルポリマー(*9) 0.25
水酸化カリウム 0.12
エデト酸二ナトリウム 0.01
火棘抽出物 0.15
カロットエキス(*10) 0.1
セイヨウナシ発酵エキス(*11) 0.1
ビルベリー葉エキス(*12) 0.1
ラズベリーケトングルコシド(*13) 0.1
海藻エキス(*14) 0.01
精製水 残 量
*7;シリコンFZ-209(日本ユニカー社製)
*8;KF-96A-200cs(信越化学工業社製)
*9;CARBOPOL 941(Noveon INC.社製)
*10;ベジタブルコラーゲン(高研社製)
*11;ファーメンテージセイヨウナシエキス(一丸ファルコス社製)
*12;キュアベリーエキス(一丸ファルコス社製)
*13;ラズベリーケトングルコシド(長谷川香料社製)
*14;マリンパージ(一丸ファルコス社製)
原料成分 配合量
エタノール 10.0
水素添加大豆リン脂質(*15) 1.0
コレステロール 0.5
ポリグリセリン脂肪酸エステル(注7) 0.2
N-メチル-L-セリン 0.01
ポリオキシエチレンメチルグルコシド(*16) 2.0
スクワラン 2.0
シクロペンタポリシロキサン 1.0
1,3-ブチレングリコール 2.0
ポリグリセリン 1.0
ロドデンドロール-D-グルコシド 2.0
アクリル酸メタクリル酸アルキル共重合体(*17) 0.2
水酸化カリウム 0.1
グリチルリチン酸ジカリウム 0.1
ヒアルロン酸ナトリウム 0.05
トリエタノールアミン 0.5
キサンタンガム 0.1
火棘抽出物 0.1
ハクガイシ加水分解エキス(*18) 0.01
スイカズラエキス(*19) 0.01
豆乳発酵液(*20) 0.01
小麦胚芽エキス(*21) 0.01
ルイボスエキス(*22) 0.01
香料 0.03
精製水 残 量
(注7)サンソフトQ-12S(太陽化学社製、HLB=16.1)
*15;レシノールS-10(日光ケミカルズ社製)
*16;NIKKOL BMG-20(日光ケミカルズ社製)
*17;PEMULEN TR-1(Noveon INC.社製)
*18;シナブランカ-WH(テクノーブル社製)
*19;ファルコレックススイカズラSB(一丸ファルコス社製)
*20;豆乳発酵液(三省製薬社製)
*21;クラリスキン(Silab社製)
*22;ファルコレックスルイボスB(N)(一丸ファルコス社製)
原料成分 配合量
スクワラン 2.0
親油型モノステアリン酸グリセリン 1.5
ステアリン酸 1.0
セタノール 0.4
ポリグリセン脂肪酸エステル(注8) 0.2
ポリグリセン脂肪酸エステル(注9) 2.0
1,3-ブチレングリコール 3.0
ロドデンドロール 1.5
トリエタノールアミン 0.2
火棘抽出物 0.05
ハス種子発酵エキス(*23) 0.05
メリアアザジラクタ葉エキス(*24) 0.05
シーラベンダーエキス(*25) 0.05
ハウチワマメエキス(*26) 0.05
ムラヤコエンジーエキス(*27) 0.05
香料 0.02
精製水 残 量
(注8)リョートーポリグリセリン酸エステル ER-30D
(三菱化学フーズ社製、HLB=10)
(注9)リョートーポリグリセリン酸エステル SWA-10D
(三菱化学フーズ社製、HLB=15)
*23;蓮醸果(テクノーブル社製)
*24;ニームリーフリキッドB(一丸ファルコス社製)
*25;シーラベンダーSC(セクマ社製)
*26;ストラクチュリン(Silab社製)
*27;ムラヤコエンジー抽出液(御木本社製)
原料成分 配合量
スクワラン 10.0
パルミチン酸イソプロピル 2.0
親油型モノステアリン酸グリセリン 1.0
ステアリン酸 7.0
ミツロウ 1.0
ショ糖脂肪酸エステル(注5) 2.5
ショ糖脂肪酸エステル(注6) 0.5
メチルフェニルポリシロキサン(*7) 0.5
1,3-ブチレングリコール 10.0
ロドデンドロール-D-グルコシド 3.0
アルカリゲネス レータス B16ポリマー 0.05
火棘抽出液 0.1
カロット液汁(*28) 0.1
オレンジ果汁(*29) 0.1
ディオスコレアコンポジタエキス(*30) 0.1
酵母エキス(*31) 0.1
サンゴ草エキス(*32) 0.1
水酸化カリウム 0.5
香料 0.03
精製水 残 量
*28;ホモフルーツキャロットN(エスペリス社製)
*29;ホモフルーツオレンジN(エスペリス社製)
*30;ディオスコレアコンポジタ根エキス(三井化学社製)
*31;イーストリキッドZB(一丸ファルコス社製)
*32;コーラルグラス(テクノーブル社製)
原料成分 配合量
モノイソステアリン酸ソルビタン 1.0
メチルシクロポリシロキサン(*33) 10.0
ジメチコンコポリオール 2.0
スクワラン 3.0
ショ糖脂肪酸エステル(注10) 0.2
塩化ナトリウム 1.0
塩化マグネシウム 1.0
ジプロピレングリコール 7.0
ヘキサノイルロドデンドロール 2.0
グリチルレチン酸ステアレート 0.1
微粒子酸化チタン(*34) 2.0
パラメトキシケイ皮酸2-エチルヘキシル 0.1
火棘抽出液 0.05
アンズ果汁(*35) 0.01
マロニエエキス(*36) 0.01
β-カロチン(*37) 0.01
香料 適 量
精製水 残 量
(注10)サーフホープ SE COSME C-1811
(三菱化学フーズ社製、HLB=11)
*33;TSF405(ジーイー東芝シリコン社製)
*34;タイペークTTO-55(A)(石原産業社製)
*35;アプリコットエキスK(エスペリス社製)
*36;マロニエ抽出液BG-J(丸善製薬社製)
*37;βカロチン(ロッシュ社製)
原料成分 配合量
エタノール 5.0
リゾレシチン 0.5
ポリグリセリン脂肪酸エステル(注3) 0.1
メチルフェニルポリシロキサン(*7) 2.0
1,3-ブチレングリコール 3.0
ポリオキシエチレンメチルグルコシド(*16) 0.5
ポリエチレングリコール1000 1.0
ロドデンドロール 3.0
アクリル酸メタクリル酸アルキル共重合体(注1) 0.1
2-メタクリロイルオキシエチルホスホリルコリン 0.5
・メタクリル酸共重合体(*38)
グリチルリチン酸ジカリウム 0.2
ニコチン酸アミド 1.0
塩化レボカルニチン 0.3
N-メチル-L-セリン 0.1
水酸化カリウム 0.07
火棘抽出物 0.1
岩白菜エキス 0.01
乳酸菌発酵液(*39) 0.1
γ-アミノ酪酸(*40) 0.02
チャ実エキス(*41) 0.01
ツバキエキス(*42) 0.01
ジュズダマエキス(*43) 0.01
ユキノシタエキス(*44) 0.01
ジオウエキス(*45) 0.01
ヒノキ水(*46) 0.01
トウヒエキス(*47) 0.01
メバロノラクトン(*48) 0.01
ホオノキ樹皮エキス(*49) 0.01
精製水 残 量
*38;Lipidure PMB(Ph10)(日本油脂社製)
*39;ホエイCPA(一丸ファルコス社製)
*40;BIO GABA(協和発酵社製)
*41;茶の実抽出物(丸善製薬社製)
*42;ツバキ種子抽出物(丸善製薬社製)
*43;ヨクイニン抽出液BG-S(丸善製薬社製)
*44;ユキノシタエキス(一丸ファルコス社製)
*45;ジオウ抽出液BG-J(丸善製薬社製)
*46;ヒノキ水B(丸善製薬社製)
*47;トウヒリキッドB(一丸ファルコス社製)
*48;メバロノラクトン(旭電化社製)
*49;ファルコレックスホオノキB(一丸ファルコス社製)
原料成分 配合量
エタノール 8.0
モノイソステアリン酸ソルビタン 1.0
ポリグリセリン脂肪酸エステル(注2) 0.1
パラメトキシケイ皮酸2-エチルヘキシル 10.0
メチルポリシロキサン(*8) 3.0
微粒子酸化チタン(*50) 3.0
微粒子酸化亜鉛(*51) 7.0
無水ケイ酸 1.0
低粘度メチルハイドロジェンポリシロキサン 0.5
パーフルオロアルキルジメチル 0.1
・トリメチルシロキシケイ酸
架橋型シリコーン末 1.0
1,3-ブチレングリコール 5.0
濃グリセリン 1.0
ヘキサノイルロドデンドロール 3.0
グリチルレチン酸ステアリル 0.1
火棘抽出物 0.05
シルク抽出液 0.01
加水分解シルク液(*52) 0.01
精製水 残 量
*50;ZnO-350(住友大阪セメント社製)
*51;タイペークTTO-55(A)(石原産業社製)
*52;シルクゲンGソルブルS(一丸ファルコス社製)
原料成分 配合量
エタノール 10.0
ポリビニルアルコール 13.0
1,3-ブチレングリコール 1.0
ジプロピレングリコール 2.0
グリセリン 2.0
メチルフェニルポリシロキサン(*7) 0.2
ミリスチン酸オクチルドデシル 0.2
ショ糖脂肪酸エステル(注1) 0.05
スクワラン 0.2
ロドデンドロール 2.0
カルボキシビニルポリマー 0.1
ヒアルロン酸ナトリウム 0.01
ヒドロキシエチルセルロース 0.05
アミノメチルプロパノール 0.05
火棘抽出物 0.05
セイヨウシロヤナギ葉エキス(*53) 0.05
精製水 残 量
*53;ASTRESSYL(Silab社製)
Claims (7)
- (a)成分がロドデンドロールである請求項1記載の皮膚外用剤。
- (b)成分がHLB10以上のショ糖脂肪酸エステル及びポリグリセリン脂肪酸エステルから選ばれる1種又は2種以上である請求項1又は2記載の皮膚外用剤。
- (d)バラ科ピラカンタ属(Rosaceae Pyracantha)の1種である中国名「火棘」(Pyracantha fortuneana)の果実の溶媒抽出物を含有することを特徴とする請求項1~3のいずれか1項に記載の皮膚外用剤。
- (a)成分を0.1~3質量%含有するものである請求項1~4のいずれか1項記載の皮膚外用剤。
- パラオキシ安息香酸エステル及び/又はフェノキシエタノールを実質的に含有しないことを特徴とする請求項1~5のいずれか1項記載の皮膚外用剤。
- ポリオキシエチレン付加型非イオン界面活性剤を実質的に含有しないことを特徴とする請求項1~6のいずれか1項に記載の皮膚外用剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008801223442A CN101909592B (zh) | 2007-12-25 | 2008-12-25 | 皮肤外用剂 |
JP2009546956A JPWO2009081587A1 (ja) | 2007-12-25 | 2008-12-25 | 皮膚外用剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-331516 | 2007-12-25 | ||
JP2007331516 | 2007-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009081587A1 true WO2009081587A1 (ja) | 2009-07-02 |
Family
ID=40800904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/003954 WO2009081587A1 (ja) | 2007-12-25 | 2008-12-25 | 皮膚外用剤 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPWO2009081587A1 (ja) |
KR (1) | KR20100099199A (ja) |
CN (1) | CN101909592B (ja) |
TW (1) | TW200930394A (ja) |
WO (1) | WO2009081587A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2950885A1 (fr) * | 2009-10-01 | 2011-04-08 | Oreal | Utilisation de derives de vanilline comme conservateur, procede de conservation, compose et composition. |
JP2012031125A (ja) * | 2010-08-03 | 2012-02-16 | Nikko Chemical Co Ltd | 紫外線吸収剤を含有する微細エマルション組成物並びに化粧料 |
FR2968657A1 (fr) * | 2010-12-13 | 2012-06-15 | Oreal | Utilisation comme conservateur de derives dimethoxy-hydroxyphenyl-alkyl substitues, procede de conservation, compose et composition |
WO2012131177A1 (fr) * | 2011-03-31 | 2012-10-04 | L'oreal | Utilisation de dérivés hydroxylés de vanilline comme conservateur, procédé de conservation, composés et composition |
WO2012137938A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
WO2012137939A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
WO2012137940A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
CN103222944A (zh) * | 2011-09-27 | 2013-07-31 | 沈志荣 | 一种含植物提取物的瞬透生肌水组合物的制备方法 |
GB2500585A (en) * | 2012-03-23 | 2013-10-02 | Univ Manchester | Use of oligosaccharides to reduce skin pigmentation |
WO2019170195A1 (de) * | 2018-03-06 | 2019-09-12 | 4Gene Gmbh | Zusammensetzung mit einem wirkstoff und einem aroma- bzw. duftstoffglykosid |
US11166886B2 (en) | 2012-12-21 | 2021-11-09 | L'oreal | Cosmetic composition |
FR3117801A1 (fr) * | 2020-12-22 | 2022-06-24 | L'oreal | Composition pour l’éclaircissement et/ou le blanchiment des matières kératineuses |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083210A (zh) * | 2013-01-25 | 2013-05-08 | 王恩瀚 | 具有美白皮肤作用的药物组合物及其制备方法和应用 |
WO2015118625A1 (ja) * | 2014-02-05 | 2015-08-13 | 株式会社マンダム | ジケトン作用抑制剤 |
CN103792302B (zh) * | 2014-02-17 | 2014-12-31 | 苏州出入境检验检疫局检验检疫综合技术中心 | 一种检测化妆品中杜鹃醇的方法 |
CN106137811B (zh) * | 2015-04-03 | 2020-08-25 | 伽蓝(集团)股份有限公司 | 一种植物提取物组合物及其用途 |
CN107049824A (zh) * | 2017-06-27 | 2017-08-18 | 上海新高姿化妆品有限公司 | 一种具有美白功效的组合物及其在化妆品中的应用 |
CN111394192B (zh) * | 2019-12-31 | 2022-09-16 | 纳爱斯浙江科技有限公司 | 一种温和无刺激的全食品级洗涤剂组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10182410A (ja) * | 1996-12-24 | 1998-07-07 | Kanebo Ltd | メラニン生成抑制剤および美白化粧料 |
JPH10265325A (ja) * | 1997-03-26 | 1998-10-06 | Kanebo Ltd | メラニン生成抑制剤及び美白化粧料 |
JPH11180852A (ja) * | 1997-12-22 | 1999-07-06 | Kanebo Ltd | 皮膚化粧料 |
JP2003321488A (ja) * | 2002-04-24 | 2003-11-11 | Hajime Ikegai | 抗菌性抽出物及びその製造方法並びに抗菌剤組成物 |
JP2008007432A (ja) * | 2006-06-27 | 2008-01-17 | Kao Corp | 皮膚外用剤 |
JP2008273851A (ja) * | 2007-04-26 | 2008-11-13 | Kao Corp | 皮膚外用剤 |
-
2008
- 2008-12-25 CN CN2008801223442A patent/CN101909592B/zh not_active Expired - Fee Related
- 2008-12-25 KR KR1020107013796A patent/KR20100099199A/ko not_active Application Discontinuation
- 2008-12-25 JP JP2009546956A patent/JPWO2009081587A1/ja not_active Withdrawn
- 2008-12-25 WO PCT/JP2008/003954 patent/WO2009081587A1/ja active Application Filing
- 2008-12-25 TW TW097150734A patent/TW200930394A/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10182410A (ja) * | 1996-12-24 | 1998-07-07 | Kanebo Ltd | メラニン生成抑制剤および美白化粧料 |
JPH10265325A (ja) * | 1997-03-26 | 1998-10-06 | Kanebo Ltd | メラニン生成抑制剤及び美白化粧料 |
JPH11180852A (ja) * | 1997-12-22 | 1999-07-06 | Kanebo Ltd | 皮膚化粧料 |
JP2003321488A (ja) * | 2002-04-24 | 2003-11-11 | Hajime Ikegai | 抗菌性抽出物及びその製造方法並びに抗菌剤組成物 |
JP2008007432A (ja) * | 2006-06-27 | 2008-01-17 | Kao Corp | 皮膚外用剤 |
JP2008273851A (ja) * | 2007-04-26 | 2008-11-13 | Kao Corp | 皮膚外用剤 |
Non-Patent Citations (1)
Title |
---|
SRINIVASA R.P. ET AL.: "Antibacterial activity of isolates from Piper longum and Taxus baccata", PHARMACEUTICAL BIOLOGY, vol. 39, no. 3, 2001, LISSE, NETHERLANDS, pages 236 - 238 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2950885A1 (fr) * | 2009-10-01 | 2011-04-08 | Oreal | Utilisation de derives de vanilline comme conservateur, procede de conservation, compose et composition. |
JP2012031125A (ja) * | 2010-08-03 | 2012-02-16 | Nikko Chemical Co Ltd | 紫外線吸収剤を含有する微細エマルション組成物並びに化粧料 |
FR2968657A1 (fr) * | 2010-12-13 | 2012-06-15 | Oreal | Utilisation comme conservateur de derives dimethoxy-hydroxyphenyl-alkyl substitues, procede de conservation, compose et composition |
WO2012080153A1 (en) * | 2010-12-13 | 2012-06-21 | L'oreal | Use of substituted dimethoxyhydroxyphenylalkyl derivatives as preservative, preserving method, compounds and composition |
WO2012131177A1 (fr) * | 2011-03-31 | 2012-10-04 | L'oreal | Utilisation de dérivés hydroxylés de vanilline comme conservateur, procédé de conservation, composés et composition |
WO2012137939A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
WO2012137938A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
WO2012137940A1 (ja) * | 2011-04-08 | 2012-10-11 | 花王株式会社 | 水中油型乳化組成物 |
CN103222944A (zh) * | 2011-09-27 | 2013-07-31 | 沈志荣 | 一种含植物提取物的瞬透生肌水组合物的制备方法 |
GB2500585A (en) * | 2012-03-23 | 2013-10-02 | Univ Manchester | Use of oligosaccharides to reduce skin pigmentation |
US10159635B2 (en) | 2012-03-23 | 2018-12-25 | Curapel (Scotland) Limited | Cosmetic and pharmaceutical uses of saccharides |
US11166886B2 (en) | 2012-12-21 | 2021-11-09 | L'oreal | Cosmetic composition |
WO2019170195A1 (de) * | 2018-03-06 | 2019-09-12 | 4Gene Gmbh | Zusammensetzung mit einem wirkstoff und einem aroma- bzw. duftstoffglykosid |
FR3117801A1 (fr) * | 2020-12-22 | 2022-06-24 | L'oreal | Composition pour l’éclaircissement et/ou le blanchiment des matières kératineuses |
Also Published As
Publication number | Publication date |
---|---|
JPWO2009081587A1 (ja) | 2011-05-06 |
KR20100099199A (ko) | 2010-09-10 |
CN101909592B (zh) | 2013-01-30 |
CN101909592A (zh) | 2010-12-08 |
TW200930394A (en) | 2009-07-16 |
TWI378799B (ja) | 2012-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009081587A1 (ja) | 皮膚外用剤 | |
JP4681512B2 (ja) | 皮膚外用剤 | |
JP4871782B2 (ja) | 皮膚外用剤 | |
WO2006126675A1 (ja) | 皮膚外用剤 | |
KR20100095447A (ko) | 여드름 피부용 피부 외용제 | |
JP4685751B2 (ja) | 美白化粧料 | |
WO2000044341A1 (fr) | Compositions destinees a un usage externe | |
JP5049638B2 (ja) | 皮膚外用剤 | |
CN1933801A (zh) | (2-羟苯基)醇的用途和含有该化合物的化妆品或治疗制剂 | |
TW202203912A (zh) | 非水性局部調配物 | |
JP4667336B2 (ja) | 皮膚外用剤 | |
JP2005120023A (ja) | 皮膚外用剤 | |
JP4685716B2 (ja) | 美白化粧料 | |
JP6194165B2 (ja) | 皮膚外用剤 | |
JPH0648935A (ja) | メラニン生成抑制外用剤 | |
KR101361430B1 (ko) | 안정성이 우수한 피부 외용제 | |
JP4704304B2 (ja) | 皮膚外用剤 | |
JP4685719B2 (ja) | 美白化粧料 | |
JPH11222412A (ja) | 皮膚外用剤 | |
JP4076477B2 (ja) | 皮膚外用剤 | |
JP2009132645A (ja) | アシル化ハイドロキノン配糖体及びそれを含有する皮膚外用剤 | |
WO2012137939A1 (ja) | 水中油型乳化組成物 | |
JP4685718B2 (ja) | 美白化粧料 | |
JP4685717B2 (ja) | 美白化粧料 | |
JP5137326B2 (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880122344.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08863590 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009546956 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20107013796 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010002990 Country of ref document: MY |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08863590 Country of ref document: EP Kind code of ref document: A1 |